TJ Biopharma key facts
as of Oct 2026- Developer of biotechnology therapies specializing in autoimmune diseases, immuno-oncology, and metabolic disorders.
- TJ Biopharma is valued at approximately $459.2M as of Oct 2026 (last reported valuation).
- It has raised $84.2M; the latest was Later Stage VC ($84.2M) in Sep 2025.
- Notable investors include HSG (Hong Kong), CICC Capital, Oriental Fortune Capital, Tailong VC, Heda Ventures — 13 tracked in total.
- Status: Privately Held (backing).
TJ Biopharma's last reported valuation, Sep 2025. Nothing priced has surfaced since.
- ·The complete investor list: 13 names
- ·Watch TJ Biopharma: the Monday email on marks, rounds and moves
TJ Biopharma funding rounds
No funding rounds for TJ Biopharma are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs TJ Biopharma
13+TJ Biopharma valuation
TJ Biopharma's last reported valuation was $459 million in Sep 2025. No priced round, secondary trade or fund mark has surfaced since.
TJ Biopharma investors
13 investors are on record for TJ Biopharma, including HSG (Hong Kong), CICC Capital, Oriental Fortune Capital and Tailong VC.
About TJ Biopharma
Developer of biotechnology therapies specializing in autoimmune diseases, immuno-oncology, and metabolic disorders. The company's offerings include monoclonal antibody drugs, growth hormone analogues, immunotherapy candidates, biologics manufacturing services and licensing partnerships, enabling accelerated clinical development and commercialisation of innovative treatments for global healthcare markets.
- Sector
- Healthcare
- HQ
- Hangzhou, China
- Founded
- 2016
- Website
- tjbio.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.